18 King Street East
Cyclica Inc. has developed, validated, patented and commercialized Ligand Express™, a cloud-based Software-as-a-Service platform that screens small-molecule drugs against repositories of structurally-characterized proteins or ‘proteomes’ to determine polypharmacological profiles. Accordingly, Ligand Express™ identifies significant protein targets using an innovative structure-based and drug-centric technology, leverages artificial intelligence to determine the drug’s effect on these targets, and visualizes the predicted drug-protein interactome using bioinformatics and systems biology. The platform provides a unique panoramic view of a small-molecule, by identifying on- and off-target interactions that may be expected, as well as those that are unanticipated. By understanding how a small-molecule drug will interact with all proteins in the body, Ligand Express™ augments scientific investigation by elucidating mechanism of action, prioritizing lead candidates, understanding side effects, as well as determining new uses for existing drugs.
April 30, 2010
24 articles with Cyclica
Cyclica and Arctoris to Expand Partnership to Advance Drug Discovery Programs for Alzheimer's Disease
Cyclica Inc., and Arctoris Ltd. have agreed to expand their partnership to progress drug discovery programs for novel neurodegenerative targets with a focus on Alzheimer’s disease.
Cyclica launches Perturba Therapeutics, a spin out from the University of Toronto, creating the next-generation oncology biotech
Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, today launches Perturba Therapeutics Inc. (“Perturba”), a spin out from the Stagljar Lab at the University of Toronto, Donnelly Centre for Cellular and Biomolecular Research.
Cyclica Recruits Big Pharma Veteran Michael Palovich as Chief Science Officer to Advance Robust Drug Discovery Pipeline
Cyclica Inc. welcomes drug discovery veteran Michael (Mike) Palovich as Chief Science Officer, Head of Drug Discovery.
Cyclica and IMPACT Therapeutics announce today that they have entered to a collaboration agreement on IMPACT Therapeutics’ differentiated targeted anti-cancer drug development.
PrecisionLife and Cyclica Sign Strategic Partnership Combining Leading Data-driven Biology and Chemistry Platforms to Create a Rapid Innovation Engine for Drug Discovery
PrecisionLife Ltd., the leading combinatorial analytics company driving understanding of disease biology and patient stratification, and Cyclica Inc., the partner of choice for data-driven drug discovery, announce that they have entered into a strategic partnership to co-market and offer their complementary computational platforms as an integrated drug discovery factory.
New findings accelerated by Cyclica’s drug discovery platform suggest lung cancer drug capmatinib demonstrates robust antiviral effects in experimental COVID-19 models.
Cerevel Therapeutics and Cyclica Announce Research Collaboration to Use Artificial Intelligence to Accelerate Discovery of Novel Medicines in Neuroscience
Cerevel will utilize Cyclica’s Ligand Express® and Ligand Design™ platforms to screen, identify, evaluate and optimize targets to develop neuroscience medicines
Led by Drive Capital, the investment round includes Chiesi Farmaceutici, GreenSky Capital, and members of management. Proceeds will advance Cyclica’s AI-augmented, polypharmacology-enabled, drug discovery platforms, Ligand Design and Ligand Express, and accelerate commercial plans to advance a growing pipeline of pre-clinical and clinical assets through an innovative decentralized partnership model.
Cyclica Forms Multi-Year and Multi-Project Drug Discovery Partnership with the Genome Institute of Singapore
Cyclica announces a multi-year and multi-project collaboration with the Genome Institute of Singapore (GIS), a research institute under the Agency for Science, Technology and Research (A*STAR). Cyclica and GIS will carry out research efforts spanning from polypharmacology profiling to novel compound design for diverse drug discovery programs in oncology and related diseases. The collaboration will leverage GIS’
China’s Institute of Materia Medica Partners With Cyclica on Innovative Drug Repurposing for COVID-19
The epidemic of COVID-19 remains a prominent healthcare challenge, affecting more than 70 countries and regions over the world.
Cyclica and AUM Biosciences to Partner on Developing Novel Cancer Therapies with Greater Precision and Speed, under Project Nexus
While there has been remarkable progress over the past few decades, cancer remains a major concern, with one in every six deaths being related to cancer.
Translational Medicine Accelerator and Cyclica Partner to Form Rare Diseases Medicine Accelerator to Advance the Discovery of Novel Therapies for Rare Diseases
Up to 10% of the world’s population suffers from one or more of the 10,000 estimated rare diseases defined by the Monarch Disease Ontology, resulting in chronic, progressive, and terminal medical conditions that are often misdiagnosed or clinically mismanaged.
In an Industry Shake Up, Cyclica Announces the Addition of Dr. Melissa Landon, former Director of Applications Science at Schrödinger, as VP, Chief Strategist.
Melissa brings to Cyclica a wealth of strong scientific expertise in informatics, computational chemistry, and structural biology
ATAI Life Sciences and Cyclica Launch Joint Venture to Revolutionize Drug Development for Mental Health Disorders
Joint venture aimed at changing the paradigm in which mental health disorders are treated.
Cyclica Collaborates With Enamine to Use REAL Technology in Its Ligand Design Platform for AI-augmented Drug Design
At least 80% of these compounds will be synthesized by Enamine within only 3-4 weeks.
To Build Stronger Partnerships Globally, Cyclica Appoints Long Time Pharma R&D Leader Vern De Biasi as VP, Global Head of Strategic Partnerships
Cyclica is pleased to announce Dr. Vern De Biasi as VP, Global Head of Strategic Partnerships.
Cyclica and University of Toronto Stagljar Lab Announce Partnership to Create the Next-Generation EGFR Inhibitors in Non-Small Cell Lung Cancer
Cyclica,, and Professor Igor Stagljar from the Donnelly Centre for Cellular and Biomolecular Research, Department of Biochemistry & Department of Molecular Genetics at the University of Toronto, announce a collaboration to optimize lead compounds and de novo design of novel compounds in an effort to advance precision medicine with the next-generation EGFR-inhibitors in non-small cell lung cancer (NSCLC)
Cyclica Launches Ligand DesignTM, a Powerful Multi-Targeted Drug Design Technology at Collision Conference Toronto
Cyclica, a leading biotechnology company that commercialized Ligand Express® announced its novel, first-in-class drug design technology, Ligand DesignTM on stage at the Collision Conference in Toronto.
Cyclica Announces the Integration of the POEM Machine Learning Predictive Engine in their Ligand Express® Platform
Cyclica, a leading biotechnology company that leverages artificial intelligence and computational biophysics to enable the discovery of new medicines, has announced the addition of a machine learning predictive engine called POEM to its Ligand Express® platform
Merck KGaA, Darmstadt, Germany, in Agreement with Cyclica for AI-augmented Screening Platform to Expand Research Capabilities
Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics